查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1414359

2024 年肝癌诊断全球市场报告

Liver Cancer Diagnostics Global Market Report 2024
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，肝癌诊断市场规模一直强劲成长。将从2023年的91.9亿美元扩大到2024年的99.5亿美元，复合年增长率为8.3%。过去几年的扩张是由于切片检查技术和组织病理学的进步、生物标记检测的进步、筛检项目的进步、基因检测的进步以及肝臟成像方式的增强。

肝癌诊断市场规模预计在未来几年将强劲成长。 2028年将以6.8%的年复合成长率（CAGR）成长至129.6亿美元。预测期内的预期增长是由于监管变化和标准化、诊断成像模式的重要性日益增加、次世代定序的开发、筛检项目的扩展和认识以及对基于生物标誌物的测试的需求不断增加。预测期内的主要趋势包括发病率和盛行率的增加、影像技术的进步、对非侵入性诊断的重视、精准医疗和个人化诊断的采用、人工智慧（AI）的整合等。Masu。

肝癌的盛行率预计将增加，从而推动肝癌诊断市场的成长。肝癌的特征是肝细胞不受控制的增殖，造成严重的健康风险。肝癌的诊断测试在诊断原发性肝癌后确定肝癌内部或周围癌细胞的扩散程度方面发挥着重要作用。根据美国癌症协会报告，美国女性肝癌和肝内胆管癌新病例呈上升趋势，到 2023 年将达到 13,230 例。预计2023年美国新增肝癌病例总数预计为41,210例，死亡病例为29,380例。这凸显了由于肝癌盛行率不断增加而迫切需要进行肝癌诊断。

乙型肝炎盛行率的不断上升预计将进一步推动肝癌诊断市场的发展。乙型肝炎是一种影响肝臟的病毒感染疾病，可引起急性和慢性症状。定期监测对于慢性B型肝炎患者评估肝臟健康状况并检测肝损伤或癌症征兆至关重要。根据美国疾病管制与预防美国的数据，约有 2.96 亿人患有B型肝炎，其中包括超过 600 万名 5 岁以下儿童。乙型肝炎盛行率的增加是肝癌诊断市场扩大的一个主要因素。

2023年肝癌诊断市场最大的地区是北美。肝癌诊断市场报告涵盖的地区包括亚太地区、西欧、东欧、北美、南美以及中东和非洲。

目录

第一章执行摘要

第二章 市场特点

第三章 市场趋势与策略

第四章宏观经济情景

  • 高通膨对市场的影响
  • 乌克兰与俄罗斯战争对市场的影响
  • COVID-19 对市场的影响

第五章世界市场规模与成长

  • 全球市场驱动因素与抑制因素
    • 市场驱动因素
    • 市场抑制因素
  • 2018-2023 年全球市场规模表现与成长
  • 全球市场规模预测与成长，2023-2028、2033

第六章市场区隔

  • 全球肝癌诊断市场，按类型、实际和预测细分，2018-2023、2023-2028、2033
  • 肝细胞癌
  • 胆管癌
  • 肝母细胞瘤
  • 其他类型
  • 全球肝癌诊断市场，依筛检细分：实际与预测，2018-2023、2023-2028、2033
  • 临床检查
  • 影像
  • 内视镜检查
  • 切片检查
  • 其他筛检
  • 全球肝癌诊断市场，依技术细分、实际及预测，2018-2023、2023-2028、2033
  • 萤光原位杂合反应（FISH）
  • 比较基因组杂合反应（CGH）
  • 免疫组织化学 (IHC)
  • 其他技术
  • 全球肝癌诊断市场，依最终用途、实际和预测细分，2018-2023、2023-2028、2033
  • 医院和诊断实验室
  • 学术研究所
  • 医药及CRO研究院

第 7 章 区域与国家分析

  • 全球肝癌诊断市场，按地区、绩效及预测，2018-2023年、2023-2028年、2033年
  • 全球肝癌诊断市场，依国家、绩效及预测，2018-2023、2023-2028、2033

第八章亚太市场

第九章 中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第14章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章 义大利市场

第20章 西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章加拿大市场

第26章 南美洲市场

第27章 巴西市场

第28章 中东市场

第29章 非洲市场

第三十章 竞争形势及公司概况

  • 肝癌诊断市场竞争形势
  • 肝癌诊断市场公司概况
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers

第31章竞争基准化分析

第 32 章竞争对手仪表板

第三十三章 重大併购

第34章 未来前景与可能性分析

第35章附录

简介目录
Product Code: r11869

“Liver Cancer Diagnostics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The liver cancer diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma; Other Types
  • 2) By Screening: Laboratory Testing; Imaging; Endoscopy; Biopsy; Other Screenings
  • 3) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
  • 4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes; Pharmaceutical And CRO Laboratories
  • Companies Mentioned: Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Qiagen NV; Thermo Fisher Scientific Inc.; Siemens Healthineers
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

The liver cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.95 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The expansion observed in the historical period can be credited to advancements in biopsy techniques and histopathology, the progress in biomarker detection, the evolution of screening programs, advancements in genetic testing, and enhancements in liver imaging modalities.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.96 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period can be ascribed to regulatory changes and standardization, the increasing significance of imaging modalities, the development of next-generation sequencing, the expansion of screening programs and awareness, and the growing demand for biomarker-based testing. Key trends in the forecast period encompass an increase in incidence and prevalence, progress in imaging technologies, emphasis on non-invasive diagnostics, the adoption of precision medicine and personalized diagnostics, and the integration of artificial intelligence (AI).

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

The growing prevalence of hepatitis B is anticipated to further boost the liver cancer diagnostics market. Hepatitis B, a viral infection affecting the liver, can lead to both acute and chronic conditions. Regular monitoring is essential for individuals with chronic hepatitis B to assess liver health and detect signs of liver damage or cancer. According to the Centers for Disease Control and Prevention, approximately 296 million people, including over 6 million children under the age of 5, are affected by hepatitis B. This growing prevalence of hepatitis B is a significant driver for the expansion of the liver cancer diagnostics market.

A prominent trend in the liver cancer diagnostics market is the focus on technological innovations. Leading companies in the market are investing in the development of innovative diagnostic technologies to enhance their market standing. In December 2021, Helio Health and Fulgent Genetics Inc. introduced HelioLiver, an advanced liquid biopsy test designed for the early detection of liver cancer. HelioLiver utilizes a multi-analyte blood test approach, incorporating serum protein indicators and cell-free DNA (cfDNA) methylation patterns. This innovative test has the potential to identify hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, allowing for early-stage detection and more effective treatment options.

Major companies operating in the liver cancer diagnostics market are strategically pursuing partnerships and collaborations to enhance their market profitability. Such collaborations aim to achieve specific business objectives and goals. For example, in August 2021, 111 Inc., a Chinese digital health platform, entered into a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co. This collaboration focuses on developing a comprehensive management platform for liver cancer patients in China, encompassing digital marketing, patient education, data analytics, and pricing monitoring.

In December 2022, Fujifilm Holdings Corporation acquired Inspirata, an oncology informatics and healthcare IT solutions provider, for an undisclosed amount. The acquisition included Dynamyx digital pathology technology and involved the integration of Inspirata's staff and clients into Fujifilm. This strategic move allows Fujifilm to expand its Synapse Enterprise Imaging portfolio, incorporating pathology data and images into electronic medical record systems to streamline cancer patient treatment and support care teams.

Major companies operating in the liver cancer diagnostics market report are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Charles Russell Bard, Hologic Inc., Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Biocare Medical LLC, Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Bio SB Inc., Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

North America was the largest region in the liver cancer diagnostics market in 2023. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Liver Cancer Diagnostics Market Characteristics

3. Liver Cancer Diagnostics Market Trends And Strategies

4. Liver Cancer Diagnostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Liver Cancer Diagnostics Market Size and Growth

  • 5.1. Global Liver Cancer Diagnostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Liver Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Liver Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Liver Cancer Diagnostics Market Segmentation

  • 6.1. Global Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Hepatoblastoma
  • Other Types
  • 6.2. Global Liver Cancer Diagnostics Market, Segmentation By Screening:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Laboratory Testing
  • Imaging
  • Endoscopy
  • Biopsy
  • Other Screenings
  • 6.3. Global Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Fluorescent In Situ Hybridization (FISH)
  • Comparative Genomic Hybridization (CGH)
  • Immunohistochemical (IHC)
  • Other Technologies
  • 6.4. Global Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Diagnostic Laboratories
  • Academic And Research Institutes
  • Pharmaceutical And CRO Laboratories

7. Liver Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Liver Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Liver Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Liver Cancer Diagnostics Market

  • 8.1. Asia-Pacific Liver Cancer Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Liver Cancer Diagnostics Market

  • 9.1. China Liver Cancer Diagnostics Market Overview
  • 9.2. China Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Liver Cancer Diagnostics Market

  • 10.1. India Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Liver Cancer Diagnostics Market

  • 11.1. Japan Liver Cancer Diagnostics Market Overview
  • 11.2. Japan Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Liver Cancer Diagnostics Market

  • 12.1. Australia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Liver Cancer Diagnostics Market

  • 13.1. Indonesia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Liver Cancer Diagnostics Market

  • 14.1. South Korea Liver Cancer Diagnostics Market Overview
  • 14.2. South Korea Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Liver Cancer Diagnostics Market

  • 15.1. Western Europe Liver Cancer Diagnostics Market Overview
  • 15.2. Western Europe Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Liver Cancer Diagnostics Market

  • 16.1. UK Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Liver Cancer Diagnostics Market

  • 17.1. Germany Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Liver Cancer Diagnostics Market

  • 18.1. France Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Liver Cancer Diagnostics Market

  • 19.1. Italy Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Liver Cancer Diagnostics Market

  • 20.1. Spain Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Liver Cancer Diagnostics Market

  • 21.1. Eastern Europe Liver Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Liver Cancer Diagnostics Market

  • 22.1. Russia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Liver Cancer Diagnostics Market

  • 23.1. North America Liver Cancer Diagnostics Market Overview
  • 23.2. North America Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Liver Cancer Diagnostics Market

  • 24.1. USA Liver Cancer Diagnostics Market Overview
  • 24.2. USA Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Liver Cancer Diagnostics Market

  • 25.1. Canada Liver Cancer Diagnostics Market Overview
  • 25.2. Canada Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Liver Cancer Diagnostics Market

  • 26.1. South America Liver Cancer Diagnostics Market Overview
  • 26.2. South America Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Liver Cancer Diagnostics Market

  • 27.1. Brazil Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Liver Cancer Diagnostics Market

  • 28.1. Middle East Liver Cancer Diagnostics Market Overview
  • 28.2. Middle East Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Liver Cancer Diagnostics Market

  • 29.1. Africa Liver Cancer Diagnostics Market Overview
  • 29.2. Africa Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Liver Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Liver Cancer Diagnostics Market Competitive Landscape
  • 30.2. Liver Cancer Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Qiagen NV
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Thermo Fisher Scientific Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Siemens Healthineers
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Liver Cancer Diagnostics Market Competitive Benchmarking

32. Global Liver Cancer Diagnostics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Liver Cancer Diagnostics Market

34. Liver Cancer Diagnostics Market Future Outlook and Potential Analysis

  • 34.1 Liver Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Liver Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Liver Cancer Diagnostics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer